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Genetic Chameleons; remember the relapsing disorders 
 
Our genetic code is satisfyingly reliable. It does not suffer circadian fluctuations - there is no need for 
an ‘early morning’ or ‘fasting’ DNA test. It does not transmute over time – there is no need to 
resample, or compare results with an aged-matched sample. It does not suffer the vagaries of the 
test-retest variation seen with an ESRs or a CK. The famous twisted-ladder of the double helix 
structure provides great physical and chemical stability. This inherent steadfastness is the tenet on 
which Michael Crichton’s Jurassic Park is based, as well as countless real and fictionalised court-
room dramas. These features may predicate the optics through which we view a genetic disorder; 
indelible, inevitable, fixed and inert. In reality no branch of medicine is as straight-forward as we 
were initially taught– and medical genetics is unrecognisable from the undergraduate lectures of 
only a couple of decades ago. Somatic variation, mosaicism and heteroplasmy are but some of the 
mechanisms that undermine the superficial but false impression of genetic constancy. 
Consider the gamut of genetic disorders that break from this architype, such as the paroxysmal 
conditions. There are the familial hemiplegic migraine disorders (CACNA1A, ATP1A2, SCN1A, PRRT2) 
that produce spells on a spectrum from episodic migraine to fulminant encephalopathy. There are 
startle disorders such as the neonatal-onset hyperekplexias (GLRA1, SLC6A6, GLRB) that produce 
easily-elicited startle responses that do not readily habituate. There are febrile seizure genes 
(SCN1A, GABRG2) – that not only produce self-limiting seizures, but intriguingly need the secondary 
stimulus of the febrile illness. In many ways these are similar to the paroxysmal kinesigenic dystonias 
in so much as the genetic fault (PRRT2, again) needs a secondary trigger.  
There are genetic disorders that are associated with relapsing and remitting episodes that persist for 
days or weeks. In Newcastle we’d perhaps first think of the encephalopathy and seizure-related 
strokes of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; 
m.3243A>G) as a great example of these inherently unstable and fluctuating genetic disorders. 
MELAS illustrates two trajectories well – the chronic and the acute. There is a steady inexorable 
decline over decades as demonstrated by dementia clinically, and progressive atrophy on MRI brain; 
both of which are exacerbated by the encephalopathic focal-seizures of MELAS.  
The painless sub-acute visual loss in Leber’s Hereditary Optic Neuropathy (mitochondrial DNA point 
mutations at 11778, 14484, and 3460) is often diagnosed late because of the broad range in age of 
onset (primary school to retirement age). A proportion of the variability in the age of onset pertains 
to an environmental trigger and asymptomatic carriers are prompted to live a virtuous life. Smoking 
tobacco and, to a lesser extent, imbibing alcohol are established provoking factors; similarly, 
smoking cessation reduces the severity of symptoms.  
The prototypic epileptic encephalopathy, Dravet syndrome (SCN1A, again) has a gestalt that varies 
depending on when you meet the patient. The first phase (6 to 18 months) is of frequent and 
unusual febrile seizures, the second (12 months to teenage years) consists of developmental 
slowing, regression, and multiple drug-refractory seizure types, and the third phase (adult) has fewer 
recognisable features. There are patterns of gait change, loss of bladder control and the fever-
sensitivity may remain, but the myoclonus may no longer predominate and the EEG may not be 
characteristic. I would wager that the majority of clinical diagnoses of Dravet in adult medicine are 
made with the 20/20 hindsight of having a definitive genetic result available. The test is now trivial 
to commission because it should be on every epilepsy gene panel. The flood gates are now open. 
Neurologists who commission genetic testing now must forge closer links with clinical genetics, and 
where available, neurogenetic MDTs because the challenge is now primarily around variant 
interpretation rather than access to gene panels or ‘hypothesis free’ testing such as sequencing the 
entire exome or genome As always if you know that you should test, but not what to test – ask for 
DNA to be extracted and stored and speak to your local clinical genetics team.  
When considering a case at grand round, if you have correctly localised the pathology and have an 
understanding of the chronology of the disease, you won’t be far wrong. Neurology has an 
abundance of these words for describing the time-course: acute, chronic, fatigable, fixed, fluctuant, 
inconsistent, progressive, relapsing, remitting, stuttering, sub-acute and more. Some of these words 
will directly narrow down the field of enquiry – so it is worth remembering the genetic chameleons. 
Particularly the conditions that initially impersonate an inflammatory or infectious illness. In this 
edition of Practical Neurology we have a case that very much fits that paradigm; acute necrotising 
encephalopathy (RANBP2).[1] 
In this genetic disorder the children (primarily) have no hallmarks of an illness until they are exposed 
to an acute infection, often influenza. This triggers a rapidly progressive encephalopathy that would 
be readily attributed to ‘post infectious’ causes and not aggressively investigated further were it not 
that this pattern can, tragically, recur in siblings. The most striking feature that separates this from 
isolated acute necrotising encephalopathy is that it can also recur in the proband so that it may 
broadly mimic a relapsing-remitting disorder. Features that suggest this genetic disorder include a 
later (teenage and older) age of onset, without abnormal liver function tests, with thalamic and 
pontine involvement on MRI.  
Consider the genetic chameleons, including those that have environmental triggers, as we evolve 
our paradigm of what constitutes a genetic disease. As more children with complex neurological 
disorders survive into adulthood we will be caring for more young adults with genetic disorders – 
with and without a diagnosis. 
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